A Virtual Reality View: Long-term Management of Atopic Dermatitis: New and Emerging Targeted Systemic Therapies
Preregistration is for planning purposes only and seating will be available on a first-come, first-served basis.
This program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee.
This program does not qualify for continuing medical education (CME) credit.
Thursday, February 28, 2019
6:30 PM – 7:00 PM: Registration/Dinner
7:00 PM – 8:00 PM: Symposium
Renaissance Washington, DC Downtown Hotel
999 9th Street, NW
Washington, DC 20001
Meeting Room: Congressional Hall A/B/C
- Virtual reality headsets provided to attendees for viewing this presentation only
- Create your own personalized poster
- Interactive, case-based learning environment
While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.
Jennifer Schoch, MD
Assistant Professor of Dermatology
Department of Dermatology
University of Florida College of Medicine
After completing the CME activity, learners should be better able to:
- Review recent pathophysiological findings in AD that have informed the selection of new therapeutic targets
- Describe best practices for severity assessment and diagnosis of moderate-to-severe AD in pediatric patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden
- Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in pediatric patients
- Discuss how different biomarkers, comorbidities and adherence barriers play a role in long-term treatment decision making for pediatric patients with AD
This activity is intended for US-based dermatologists and other health care professionals who diagnose, treat, and/or manage patients with AD.
Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For questions, please contact Med Learning Group at firstname.lastname@example.org.
Privacy and confidentiality policy statement information is available at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at email@example.com
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.